Efficacy and safety of rivaroxaban for thromboprophylaxis after orthopedic surgery: a Meta-analysis
10.13699/j.cnki.1001-6821.2017.14.023
- VernacularTitle:利伐沙班用于骨科术后患者静脉血栓栓塞预防有效性和安全性的Meta分析
- Author:
Xia YANG
1
;
Shu-Jie DONG
;
Suo-Di ZHAI
Author Information
1. 北京大学第三医院药剂科
- Keywords:
rivaroxaban;
venous thromboembolism;
low molecular heparin;
asipirin;
apixaban;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(14):1366-1370
- CountryChina
- Language:Chinese
-
Abstract:
Objective To further evaluate the efficacy and safety of rivaroxaban in the thromboprophylaxis after orthopedic surgery.Methods PubMed,EmBase,Cochrane Library,Web of Science,Clinical Trials,CNKI,CBM and Wanfang database were systematically searched.All databases had been searched from established up to August 2016.All randomized controlled trials (RCTs) of rivaroxaban therapy in patients after orthopedic surgery were selected.Meta-analysis was carried out by using RevMan 5.3 software.The incidence of total venous thromboembolism (VTE),major VTE,deep vein thrombosis (DVT),pulmonary embolism (PE),all-cause mortality,symptomatic VTE,bleeding,major bleeding,clinical relevant non-major bleeding (CRNMB),minor bleeding and wound complication were compared and the results were presented with risk ratio (RR) with 95％ confidence interval (CI).Results Totally 32 RCTs of 17061 cases were included in this study,including 9167 cases accepted rivaroxaban (treatment group),other of 7894 cases accepted other drugs (control group).The results of Meta-analysis were as follows.The incidence of symptomatic VTE,total VTE,major VTE and DVT in the rivaroxaban group was lower than that in the low molecular heparin group (P ＜ 0.05).The incidence of total VTE,and DVT in rivaroxaban group was lower than that in aspirin group (P ＜ 0.05).There was no significant difference in the efficacy and safety between the rivaroxaban and apixaban group (P ＞ 0.05).Conclusion In the thromboprophylaxis after orthopedic surgery,efiicacy of rivaroxban is better than that of traditional anticoagulant therapy and it will not increase the risk of adverse events such as bleeding and wound complication.
